SCHEDULE 13D/A: Gilead Sciences Boosts Stake in Arcus Biosciences to 35% Through Latest Public Offering and Strategic Option

Sentiment:

Schedule 13D Amendment 5 March 2025 10:00 PM

Gilead Sciences, Inc. has increased its beneficial ownership in Arcus Biosciences, Inc. to 35% through a series of stock purchases, including a recent public offering, reinforcing their strategic collaboration.

Capital raiseGilead acquired 1,363,636 shares of Common Stock in Arcus Biosciences' most recent public offering on February 18, 2025, at a price of $11.00 per share, totaling $14,999,996.Gilead also holds a five-year option to purchase additional shares from Arcus, up to a maximum of 35% of the Issuer's then-outstanding Common Stock, which represents a potential future capital raise for Arcus.

Worse than expectedThe public offering price of $11.00 per share for the most recent capital raise is significantly lower than all previous per-share prices paid by Gilead in prior investment rounds ($27.50, $33.54, $39.00, $19.26, $21.00). This indicates a lower valuation for Arcus Biosciences in this specific capital raise compared to its historical funding rounds with Gilead.

Summary

Gilead Sciences, Inc. (Gilead) has filed an Amendment No. 4 to its Schedule 13D, detailing its increased beneficial ownership in Arcus Biosciences, Inc. (Arcus) to 35% of the outstanding common stock.
Gilead now beneficially owns 39,691,649 shares of Arcus Common Stock, which includes 8,266,889 Option Shares that Gilead has the right to purchase.
The latest acquisition by Gilead involved 1,363,636 shares of Common Stock in Arcus's public offering on February 18, 2025, at a price of $11.00 per share, totaling $14,999,996.
This recent purchase adds to previous acquisitions: 2,200,000 shares in June 2020 at $27.50/share, 5,963,029 shares in July 2020 at $33.54/share, 5,650,000 shares in February 2021 at $39.00/share, 1,010,000 shares in June 2023 at $19.26/share, and 15,238,095 shares in January 2024 at $21.00/share.
Gilead's investment is part of a broader Option, License and Collaboration Agreement established in May 2020, granting Gilead an exclusive option to acquire licenses to Arcus's clinical programs.
The Equity Agreements between Gilead and Arcus include standstill and lock-up provisions, and grant Gilead the right to designate three individuals to Arcus's board of directors.
Gilead's total investment in Arcus shares, excluding the option shares, amounts to approximately $845.3 million across these various purchases.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the recent public offering price is lower than previous rounds, Gilead's continued and increasing strategic investment, including the exercise of options to reach 35% ownership, demonstrates strong long-term commitment and confidence in Arcus Biosciences and their collaboration. This ongoing support provides stability and validation for Arcus.

Positives

Gilead's continued and increasing investment in Arcus Biosciences, reaching 35% beneficial ownership, signals strong confidence in the strategic collaboration and Arcus's clinical programs.
The existing Option, License and Collaboration Agreement provides Arcus with a significant strategic partner and potential funding source for its clinical development programs.
Gilead's right to designate three board members offers strategic guidance and alignment, potentially enhancing Arcus's corporate governance and strategic direction.
The five-year option for Gilead to purchase additional shares up to 35% of Arcus's outstanding common stock provides a potential future capital infusion for Arcus at a premium to market or the initial purchase price.

Negatives

The recent public offering price of $11.00 per share is significantly lower than all previous purchase prices by Gilead, including $27.50, $33.54, $39.00, $19.26, and $21.00, indicating a lower valuation for Arcus in this specific capital raise compared to prior rounds.
The lock-up agreement restricts Gilead from selling or hedging its shares for 60 days post-offering, limiting its immediate liquidity options for its Arcus holdings.

Risks

The document does not detail specific operational or financial risks for Arcus Biosciences, focusing instead on the terms of Gilead's investment and associated agreements.
Gilead's option to purchase additional shares is at a price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) or the Initial Purchase Price of $33.54, which could be a risk for Arcus if its market price remains significantly below this floor, potentially limiting Gilead's incentive to exercise the option at a higher price.

Future Outlook

Gilead Sciences retains a five-year option to purchase additional shares of Arcus Biosciences' Common Stock, allowing it to maintain up to 35% ownership. The purchase price for these option shares will be the greater of a 20% premium to market (based on a trailing five-day average closing price) or the Initial Purchase Price of $33.54. Gilead intends to continue reviewing its investment and Arcus's business affairs, reserving the right to formulate future plans or proposals regarding Arcus, including potential strategic transactions.

Management Comments

Andrew D. Dickinson, Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc., certified the information set forth in the statement.

Industry Context

This filing highlights the ongoing trend of larger pharmaceutical companies forming strategic collaborations and making significant equity investments in smaller biotechnology firms to access innovative clinical programs and pipelines. Gilead's continued commitment to Arcus Biosciences, a company focused on cancer immunotherapies, underscores the strategic importance of oncology and immunology assets in the biopharmaceutical industry. Such partnerships allow larger companies to diversify their portfolios and smaller companies to secure funding and leverage the larger partner's development and commercialization expertise.

Comparison to Industry Standards

The document does not provide specific comparable companies, projects, or results to assess the financial outcomes or strategic positioning against global industry benchmarks. It primarily details Gilead's investment activities and contractual agreements with Arcus Biosciences.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Existing Arrangement	Gilead has the right to designate three individuals to be appointed to Arcus Biosciences' board of directors, as per the Amended and Restated Investor Rights Agreement.	N/A (existing right)	Enhances strategic alignment and oversight between Gilead and Arcus, providing Gilead with direct influence on corporate strategy and governance.
Existing Arrangement	The Equity Agreements include standstill and lock-up provisions, which restrict certain actions by Gilead regarding Arcus's securities.	N/A (existing provisions)	Provides stability by limiting Gilead's ability to rapidly alter its stake or engage in hostile actions, while also restricting its immediate liquidity.

Legal Proceedings

Neither Gilead Sciences, Inc. nor any person named in Schedule I has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or been a party to a civil proceeding resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Related Party Transactions

Gilead Sciences, Inc.'s multiple purchases of Arcus Biosciences' Common Stock, including the recent public offering and previous private placements, constitute related party transactions due to their strategic collaboration and Gilead's significant ownership stake.
The Option, License and Collaboration Agreement between Gilead and Arcus is a significant related party arrangement, granting Gilead exclusive options to Arcus's clinical programs.

Stakeholder Impact

Shareholders: The recent public offering at a lower price may cause some dilution for existing shareholders, but Gilead's continued investment and strategic collaboration could provide long-term value and stability.
Employees: The ongoing strategic partnership and significant investment from Gilead likely provide a sense of stability and potential for continued research and development, benefiting employees.
Customers/Patients: The collaboration aims to advance clinical programs, which could ultimately lead to new medicines, benefiting future patients.
Creditors: Gilead's substantial equity investment strengthens Arcus's financial position, potentially improving its creditworthiness.

Next Steps

Gilead Sciences intends to continue reviewing its investment in Arcus Biosciences and its business affairs, financial position, performance, and other investment considerations.
Gilead may engage in discussions with Arcus's management, directors, other stockholders, and other persons regarding the Issuer's management, operations, business, assets, capitalization, financial condition, strategic plans, governance, and future.
Gilead reserves the right to consider additional courses of action, including formulating future plans or proposals concerning events or transactions described in Item 4(a) through (j) of Schedule 13D.
The Lock-Up Agreement restricts Gilead from transferring or hedging its shares for 60 days after the final prospectus relating to the Public Offering.

Key Dates

Date	Description
2020-05-27	Gilead and Arcus entered into an Option, License and Collaboration Agreement and a Common Stock Purchase Agreement.
2020-06-02	Completion of the 2020 Public Offering where Gilead purchased 2,200,000 shares.
2020-07-13	Initial Purchase of 5,963,029 shares by Gilead occurred.
2020-07-17	Initial Schedule 13D filed by Gilead.
2021-01-31	Gilead entered into the Amended and Restated Purchase Agreement.
2021-02-01	Second Purchase of 5,650,000 shares by Gilead occurred.
2021-02-02	Amendment No. 1 to Schedule 13D filed.
2023-06-27	Gilead entered into the Second Amended and Restated Purchase Agreement.
2023-06-28	Third Purchase of 1,010,000 shares by Gilead occurred.
2023-07-06	Amendment No. 2 to Schedule 13D filed.
2024-01-29	Gilead entered into the Third Amended and Restated Purchase Agreement and the Fourth Purchase of 15,238,095 shares occurred.
2024-01-31	Amendment No. 3 to Schedule 13D filed.
2025-02-17	Lock-Up Agreement dated.
2025-02-18	Date of event requiring filing of this statement; Gilead acquired shares in Arcus's most recent public offering.
2025-02-19	Arcus's most recent public offering completed.
2025-02-20	Amendment No. 4 (this filing) was timely filed, but Schedule I was improperly filed as correspondence.
2025-03-05	Date of signature for the refiled Amendment No. 4.
2025-03-31	Termination date for the Lock-Up Agreement if the Underwriting Agreement has not been executed by this date (subject to a 90-day extension).

Recommendation

hold

Keywords

Gilead Sciences, Arcus Biosciences, SEC Filing, Schedule 13D, Beneficial Ownership, Stock Purchase, Public Offering, Collaboration Agreement, Biotechnology, Pharmaceuticals, Investment, Equity Agreements, Lock-Up Agreement

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.